Cladribine as a therapeutic option in multiple sclerosis

被引：10

作者：

Warnke, Clemens ^{[1
]}

Leussink, Verena I. ^{[1
]}

Goebels, Norbert ^{[1
]}

Aktas, Orhan ^{[1
]}

Boyko, Alexey ^{[2
,3
]}

Kieseier, Bernd C. ^{[1
]}

Hartung, Hans-Peter ^{[1
]}

机构：

[1] Univ Dusseldorf, Dept Neurol, Fac Med, D-40225 Dusseldorf, Germany

[2] Russian State Med Univ, Dept Neurol & Neurosurg, Moscow 117437, Russia

[3] Moscow MS Ctr, Moscow, Russia

来源：

CLINICAL IMMUNOLOGY | 2012年 / 142卷 / 01期

关键词：

Cladribine; Multiple sclerosis; Immunosuppressant; Oral drugs; DOUBLE-BLIND; 2-CHLORODEOXYADENOSINE; TOXICITY; 2-CHLORO-2'-DEOXYADENOSINE; APOPTOSIS; TABLETS; SAFETY; CELLS; TRIAL;

D O I：

10.1016/j.clim.2011.05.009

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

There is an unmet need for more potent and convenient drugs in the treatment of patients diagnosed with multiple sclerosis (MS). Among five currently investigated oral drugs with an ongoing or completed phase III program, promising efficacy data for oral cladribine have recently been published. However, benefits need to be weighed against potential risks to define the role of this compound within current treatment regimens. Here we review present data on efficacy of oral cladribine and discuss known and anticipated risks of this drug. (C) 2011 Published by Elsevier Inc.

引用

页码：68 / 75

页数：8

共 50 条

[41] Personalised dosing of cladribine for people with multiple sclerosis
Mao, Zhifeng
Alvarez-Gonzalez, Cesar
Yildiz, Ozlem
Allen-Philbey, Kimberley
Turner, Benjamin
Gnananpavan, Sharmilee
Marta, Monica
Mathews, Joela
Giovannoni, Gavin
Baker, David
Schmierer, Klaus
NEUROLOGY, 2018, 90
[42] Cladribine Tablets' Potential in Multiple Sclerosis Treatment
Costello, Kathleen
Sipe, Jack C.
JOURNAL OF NEUROSCIENCE NURSING, 2008, 40 (05) : 275 - 280
[43] Intravenous immunglobulins before, during and after pregnancy - therapeutic option in multiple sclerosis?
Ringel, I
Adler, S
Zettl, U
MULTIPLE SCLEROSIS, 2004, 10 (7032): : S258 - S258
[44] The CLARITY study (CLAdRIbine tablets Treating multiple sclerosis orallY): design of a Phase III trial of oral cladribine in relapsing multiple sclerosis
Giovannoni, G.
Comi, G.
Cook, S.
Beelke, M.
Rieckmann, P.
Sorensen, P. S.
Vermersch, P.
MULTIPLE SCLEROSIS, 2007, 13 : S245 - S245
[45] The therapeutic effect of cladribine on MRI disease activity in multiple sclerosis patients with and without enhancing lesions at baseline
Massimo, F
Comi, G
MULTIPLE SCLEROSIS, 1998, 4 (06): : 506 - 506
[46] CANCER RISK IN MULTIPLE SCLEROSIS PATIENTS TAKING CLADRIBINE
Pakpoor, Julia
Disanto, Giulio
Altmann, Daniel R.
Pavitt, Sue
Turner, Benjamin
Calado-Marta, Monica
Juliusson, Gunnar
Baker, David
Chataway, Jeremy
Schmierer, Klaus
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 (10):
[47] Recommendations for the use of cladribine tablets in recurring multiple sclerosis
Oreja-Guevara, Celia
Garcia-Merino, Juan A.
Saiz, Albert
Rodriguez-Antiguedad, Alfredo
Alvarez-Cermeno, Jose C.
Estrada-Perez, Vicente
Izquierdo, Guillermo
Fernandez, Oscar
REVISTA DE NEUROLOGIA, 2019, 69 : S1 - S9
[48] Cladribine has potential in multiple sclerosis, but is not without toxicity
不详
Drugs & Therapy Perspectives, 1998, 12 (12) : 1 - 4
[49] Cladribine: Mode of Action and Implications for Treatment of Multiple Sclerosis
Leist, Thomas P.
Weissert, Robert
CLINICAL NEUROPHARMACOLOGY, 2011, 34 (01) : 28 - 35
[50] Eyebrow alopecia associated with cladribine treatment for multiple sclerosis
Budimkic, Maja Stefanovic
Ivanovic, Jovana
Momcilovic, Nikola
Mesaros, Sarlota
Drulovic, Jelena
NEUROLOGICAL SCIENCES, 2023, 44 (10) : 3735 - 3736

← 1 2 3 4 5 →